My internship at Dyne Therapeutics exposed me to the harsh reality of rare disease R&D. I worked on a therapy for Metachromatic Leukodystrophy (MLD) that reached the "go/no go" checkpoint with solid data from mice and cells. The company chose not to proceed—with only a few thousand U.S. patients, the therapy was deemed "uneconomical" for the millions needed for clinical trials. I learned this is common: biotech companies can't survive studying molecules that serve markets the size of "two apartment buildings in China," as my supervisor put it. I grew aware that scientific discoveries alone don't save lives. My postgraduate plans are now twofold. Near term, I'll pursue a PhD in neurobiology focused on the molecular mechanisms of ALS, exploring how AI can push foundational science and therapeutic development. Long term, I aspire to have my own biotech company, focused on rare neuromuscular diseases. I hope to complement what I learned from research, as well as business to help cure neuromuscular diseases.